Mandate

VINGE ADVISED THE UNDERWRITERS IN RELATION TO NORDAX’S LISTING ON NASDAQ STOCKHOLM

June 22, 2015

Vinge advised Morgan Stanley & Co International plc, Carnegie Investment Bank AB (publ), Citigroup Global Markets Ltd and ABG Sundal Collier AB in relation to Nordax listing on Nasdaq Stockholm. Nordax’s principal shareholder is Vision Capital. A prospectus was published on 4 June 2015 and the first day of trading on Nasdaq Stockholm was on 17 June 2015. The price in the offering was set at SEK 45. The total value of the offering amounts to SEK 2.847 billion, assuming that the over-allotment option is exercised in full.

Nordax is a leading niche bank in the Nordic region providing unsecured consumer loans and deposit accounts to about 95,000 customers in Sweden, Norway, Finland, Denmark and Germany. As of 31 March 2015 lending to the general public amounted to SEK 10.3 billion and deposits amounted to SEK 6.5 billion.

Vinge’s team consisted mainly of responsible partner Charlotte Levin and associates Joakim Hagberg, Sabina Börjesson and Joel Wahlberg, and Axel Hedberg regarding regulatory questions.

Related

Vinge advises HealthCap in conjunction with an investment in Neobiomics

HealthCap is investing in Neobiomics AB, which develops products in the neonatal field. Neobiomics’ flagship product, Proprems, is a probiotic dietary supplement developed for preterm infants.
May 22, 2026

Vinge advises Sveafastigheter in its merger with KlaraBo

Vinge advises Sveafastigheter AB (publ) in its merger with KlaraBo Sverige AB.
May 22, 2026

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026